Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21424123 | 1.00 | GBA1 (0.35) | GBA1 | |
| SCHEMBL22920432 | 1.00 | GBA1 (0.35) | GBA1 | |
| SCHEMBL23054500 | 1.00 | GBA1 (0.35) | GBA1 | |
| SCHEMBL21424190 | 1.00 | GBA1 (0.35) | GBA1 | |
| SCHEMBL21423721 | 0.79 | — | — | |
| SCHEMBL23054423 | 0.79 | — | — | |
| SCHEMBL24536418 | 0.79 | — | — | |
| SCHEMBL21424040 | 0.79 | — | — | |
| SCHEMBL19122476 | 0.79 | GBA1 (0.38) | GBA1 | |
| SCHEMBL21423715 | 0.78 | GBA1 (0.33) | GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11547709-B2 | Methods of treating disorders associated with castor | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210061788-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20210023081-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11547709-B2 | Methods of treating disorders associated with castor | HMGCR, GCDH, CYP11A1 | GBA1 283/4885 |
| US-20210061788-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | PANK2, PANK1, PANK3 | GBA1 1330/4885 |
| US-20210023081-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | GBA1 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.